Big Data is commercial dynamite for pharma – how can you unleash its power?

Big Data is here to stay. Not just a fad, it’s fundamentally changing the way pharma companies operate and providing a route to better commercial results. What are the key challenges and opportunities? What does best practice look like? Ultimately, how can the commercial benefits of Big Data be realised?

Powering Commercial Effectiveness Through Big Data and Analytics explores how Big Data is evolving beyond the patient experience and coming of age. Read it to hear from 11 experts at the forefront of pharma’s data revolution.

“Data alone has little value. It is the insight we glean from analysing it. Pharma has no chance of making money without making cases for change, defining burden or proving effectiveness in the real world. It simply cannot do these things without first connecting data for analysis. Hassan Chaudhury, Chief Commercial Officer, Health iQ

Report Features

Unique insights from experts in Big Data and analytics from companies such as AstraZeneca, Bayer, Janssen and J&J

Experts Interviewed for This Report

Peter Barschdorff: Vice President of Business Insights at Bayer: Market Research, Commercial Analytics and Commercial Reporting (Quotes attributed to him are his personal opinion and do not in any way represent Bayer Pharmaceuticals’ opinions or business practices)

Hassan Chaudhury: Chief Commercial Officer, Health iQ

David Latshaw II: Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson

Manish Mathur: Senior Director, Data Strategy and Management for Commercial Excellence, at Janssen Pharmaceuticals, of Johnson & Johnson (Views made in this report are his personal opinion and are not intended to represent the views of Johnson & Johnson)

Key Quotes

“Data alone has little value. It is the insight we glean from analysing it. Pharma has no chance of making money without making cases for change, defining burden or proving effectiveness in the real world. It simply cannot do these things without first connecting data for analysis.

Hassan Chaudhury, Chief Commercial Officer, Health iQ

“An often overlooked aspect of Big Data is how it relates to the manufacturing process itself. Over the past 5–10 years, there has been a concerted effort in creating systems that record real-time process data, house batch information and analytical test data. The issue with these data storage systems is that they are segregated and often do not have a common format, which leads to a wealth of ‘dark data’ that we put so much effort into collecting, but not utilising to its full potential.”

Dave Latshaw IIScientist, Janssen Pharmaceuticals

“In the past, there was a lot of emphasis placed on relationships. But as the number of channels continues to grow, in addition to relationships, you also need to take a very important note of the insights that you’re able to gather from multiple channels. Sales people are not going to sit and fiddle with all sorts of IT tools. Without having a really good analytical ability, you cannot get through to people in the field in a way where they can make decisions very quickly.”